Strategic AI in Pharma Operations

Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

I currently serve as Enterprise Capabilities Lead for Roche Pharma, having previously held senior leadership roles, including Head of Global End-to-End Planning at Biogen and Senior Director of Global Forecasting at Bristol Myers Squibb. My career encompasses extensive experience in global supply chain transformations, forecasting centers of excellence, and S&OP design across the life sciences and FMCG sectors, including tenures at Mars Inc. and SABMiller. I specialize in leveraging data analytics and digital transformation, including AI/genAI, to elevate Integrated Business Planning (IBP) and build resilient, patient-centric supply chains.

Q2. How is Integrated Business Planning (IBP) evolving from a coordination tool to a true value-creation engine in pharma?

IBP is shifting from a basic volume-matching and coordination exercise to a dynamic, financially integrated operating model. In the pharma industry, we are increasingly leveraging big data and predictive analytics to connect patient demand signals directly with end-to-end supply networks. By incorporating rapid scenario planning and real-time financial alignment, IBP now serves as a strategic compass that drives profitability, resource optimization, and enterprise agility rather than merely operational consensus.

Q3. Do…